These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
192 related articles for article (PubMed ID: 33341068)
21. The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity. Stanietsky N; Simic H; Arapovic J; Toporik A; Levy O; Novik A; Levine Z; Beiman M; Dassa L; Achdout H; Stern-Ginossar N; Tsukerman P; Jonjic S; Mandelboim O Proc Natl Acad Sci U S A; 2009 Oct; 106(42):17858-63. PubMed ID: 19815499 [TBL] [Abstract][Full Text] [Related]
22. Nonfucosylation of an anti-TIGIT antibody enhances FcγR engagement, driving innate immune activation and antitumor activity. Smith AJ; Thurman RE; Zeng W; Grogan B; Lucas S; Gutierrez G; Heiser RA; Wo SW; Blackmarr A; Peterson S; Gardai SJ Front Immunol; 2023; 14():1280986. PubMed ID: 38022590 [TBL] [Abstract][Full Text] [Related]
23. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Moretta A; Bottino C; Vitale M; Pende D; Cantoni C; Mingari MC; Biassoni R; Moretta L Annu Rev Immunol; 2001; 19():197-223. PubMed ID: 11244035 [TBL] [Abstract][Full Text] [Related]
24. Enhanced antitumor efficacy of a novel oncolytic vaccinia virus encoding a fully monoclonal antibody against T-cell immunoglobulin and ITIM domain (TIGIT). Zuo S; Wei M; He B; Chen A; Wang S; Kong L; Zhang Y; Meng G; Xu T; Wu J; Yang F; Zhang H; Wang S; Guo C; Wu J; Dong J; Wei J EBioMedicine; 2021 Feb; 64():103240. PubMed ID: 33581644 [TBL] [Abstract][Full Text] [Related]
25. Hemin blocks TIGIT/PVR interaction and induces ferroptosis to elicit synergistic effects of cancer immunotherapy. Zhou X; Li Y; Zhang X; Li B; Jin S; Wu M; Zhou X; Dong Q; Du J; Zhai W; Wu Y; Qiu L; Li G; Qi Y; Zhao W; Gao Y Sci China Life Sci; 2024 May; 67(5):996-1009. PubMed ID: 38324132 [TBL] [Abstract][Full Text] [Related]
26. TIGIT immune checkpoint blockade enhances immunity of human peripheral blood NK cells against castration-resistant prostate cancer. Wang F; Liu S; Liu F; Xu T; Ma J; Liang J; Wang J; Liu D; Yang F; Li J; Xing N Cancer Lett; 2023 Aug; 568():216300. PubMed ID: 37414394 [TBL] [Abstract][Full Text] [Related]
27. CD155-TIGIT Axis as a Therapeutic Target for Cancer Immunotherapy. Mu Y; Guan X Curr Med Chem; 2024; 31(13):1634-1645. PubMed ID: 38666504 [TBL] [Abstract][Full Text] [Related]
28. Analysis of tumor-infiltrating NK and T cells highlights IL-15 stimulation and TIGIT blockade as a combination immunotherapy strategy for soft tissue sarcomas. Judge SJ; Darrow MA; Thorpe SW; Gingrich AA; O'Donnell EF; Bellini AR; Sturgill IR; Vick LV; Dunai C; Stoffel KM; Lyu Y; Chen S; Cho M; Rebhun RB; Monjazeb AM; Murphy WJ; Canter RJ J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33158916 [TBL] [Abstract][Full Text] [Related]
29. Structural and functional characterization of a monoclonal antibody blocking TIGIT. Jeong BS; Nam H; Lee J; Park HY; Cho KJ; Sheen JH; Song E; Oh M; Lee S; Choi H; Yang JE; Kim M; Oh BH MAbs; 2022; 14(1):2013750. PubMed ID: 35090381 [TBL] [Abstract][Full Text] [Related]
30. TgMab-2: An Anti-human T Cell Immunoglobulin and Immunoreceptor Tyrosine-Based Inhibitory Motif Domain Monoclonal Antibody for Immunocytochemistry. Saito M; Suzuki H; Kaneko MK; Kato Y Monoclon Antib Immunodiagn Immunother; 2022 Jun; 41(3):157-162. PubMed ID: 35736625 [TBL] [Abstract][Full Text] [Related]
31. Immune checkpoint markers and anti-CD20-mediated NK cell activation. Wang Z; Weiner GJ J Leukoc Biol; 2021 Oct; 110(4):723-733. PubMed ID: 33615552 [TBL] [Abstract][Full Text] [Related]
32. Blockade of CD112R and TIGIT signaling sensitizes human natural killer cell functions. Xu F; Sunderland A; Zhou Y; Schulick RD; Edil BH; Zhu Y Cancer Immunol Immunother; 2017 Oct; 66(10):1367-1375. PubMed ID: 28623459 [TBL] [Abstract][Full Text] [Related]
33. Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells. Romagné F; André P; Spee P; Zahn S; Anfossi N; Gauthier L; Capanni M; Ruggeri L; Benson DM; Blaser BW; Della Chiesa M; Moretta A; Vivier E; Caligiuri MA; Velardi A; Wagtmann N Blood; 2009 Sep; 114(13):2667-77. PubMed ID: 19553639 [TBL] [Abstract][Full Text] [Related]
34. Adaptive NK Cells with Low TIGIT Expression Are Inherently Resistant to Myeloid-Derived Suppressor Cells. Sarhan D; Cichocki F; Zhang B; Yingst A; Spellman SR; Cooley S; Verneris MR; Blazar BR; Miller JS Cancer Res; 2016 Oct; 76(19):5696-5706. PubMed ID: 27503932 [TBL] [Abstract][Full Text] [Related]
35. A novel anti-LAG-3/TIGIT bispecific antibody exhibits potent anti-tumor efficacy in mouse models as monotherapy or in combination with PD-1 antibody. Dai T; Sun H; Liban T; Vicente-Suarez I; Zhang B; Song Y; Jiang Z; Yu J; Sheng J; Lv B Sci Rep; 2024 May; 14(1):10661. PubMed ID: 38724599 [TBL] [Abstract][Full Text] [Related]
36. NK Cell Dysfunction and Checkpoint Immunotherapy. Bi J; Tian Z Front Immunol; 2019; 10():1999. PubMed ID: 31552017 [TBL] [Abstract][Full Text] [Related]
37. Contribution of inhibitory receptor TIGIT to NK cell education. He Y; Peng H; Sun R; Wei H; Ljunggren HG; Yokoyama WM; Tian Z J Autoimmun; 2017 Jul; 81():1-12. PubMed ID: 28438433 [TBL] [Abstract][Full Text] [Related]
38. An engineered oncolytic vaccinia virus encoding a single-chain variable fragment against TIGIT induces effective antitumor immunity and synergizes with PD-1 or LAG-3 blockade. Zuo S; Wei M; Xu T; Kong L; He B; Wang S; Wang S; Wu J; Dong J; Wei J J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34949694 [TBL] [Abstract][Full Text] [Related]
39. Characterization of ASP8374, a fully-human, antagonistic anti-TIGIT monoclonal antibody. Shirasuna K; Koelsch G; Seidel-Dugan C; Salmeron A; Steiner P; Winston WM; Brodkin HR; Nirschl CJ; Abbott S; Kinugasa F; Sugahara S; Ohori M; Takeuchi M; Hicklin DJ; Yoshida T Cancer Treat Res Commun; 2021; 28():100433. PubMed ID: 34273876 [TBL] [Abstract][Full Text] [Related]
40. Immune Exhaustion of T Cells in Alveolar Echinococcosis Patients and Its Reversal by Blocking Checkpoint Receptor TIGIT in a Murine Model. Zhang C; Lin R; Li Z; Yang S; Bi X; Wang H; Aini A; Zhang N; Abulizi A; Sun C; Li L; Zhao Z; Qin R; Li X; Li L; Aji T; Shao Y; Vuitton DA; Tian Z; Wen H Hepatology; 2020 Apr; 71(4):1297-1315. PubMed ID: 31410870 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]